- Home
- INO vs EQ Comparison
INO vs EQ Comparison
Compare INO & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INO | EQ |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 129.0M |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | INO | EQ |
|---|---|---|
| Price | $1.34 | $2.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $6.75 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 3.2M | 302.2K |
| Earning Date | 05-08-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,220,086.00 | $41,095,000.00 |
| Revenue This Year | $20,156.19 | N/A |
| Revenue Next Year | $421.95 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.37 | N/A |
| 52 Week Low | $1.03 | $0.29 |
| 52 Week High | $2.86 | $2.70 |
Technical Indicators
Market Signals| Indicator | INO | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 54.70 | 62.86 |
| Support Level | $1.03 | $1.60 |
| Resistance Level | $1.52 | $2.49 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 35.51 | 91.46 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.